November 7, 2009
A combination of new biotechnology research techniques and manufacturing technologies has reinvigorated the global vaccines industry. Vaccines are now targeting larger markets following increasing demand and improved profitability. The WHO estimates that more than 75 vaccines are currently at various stages of development for a range of diseases including AIDs, diarrhoea, pneumococcal disease, cervical cancer and smoking.
‘The Vaccines Market Outlook To 2014’ is a report published by Business Insights that provides a comprehensive analysis of key vaccine classes and leading companies within the global vaccines market. Leading brands for each major indication within both adult and pediatric population segments are assessed to identify key growth areas and leading products through to 2014. The competitive landscape of the market is examined, based on an analysis of portfolio , pipeline strength and growth strategies for each major vaccine manufacturer. This report also reviews the factors and underlying trends that are currently shaping market development, and provides forecasts for currently marketed and key pipeline products over the 2009-14 period.
The global vaccines market generated sales of $11.1bn in 2008, an increase of 0.5% over 2007. Merck/Sanofi-Aventis’ Gardasil led the market with sales of $1.6bn in 2008, while Wyeth’s Prevnar followed with $1.4bn. The top 10 brands accounted for 56.7% of the market.
Pneumococcal vaccines led the pediatric vaccines segment in 2008, with Wyeth’s Prevnar accumulating sales of $1.4bn. These were followed by DTP vaccines led by GSK’s Infanrix Hexa, which registered $281m sales. Emerging segments in the pediatric space include MMRV (MMR+ varicella), rotaviral and
HPV vaccines formed the single largest adult vaccines segment in 2008 with Merck/Sanofi-Aventis’ Gardasil posting sales of $1.6bn. These were followed by the fragmented influenza segment, which continues to be a major sales driver for vaccine developers. Hepatitis vaccines also captured a major share of the adult vaccines market.
Wyeth’s Prevnar 13vPnC and Novartis’ Menveo are among the most promising vaccines in the industry pipeline. GSK’s Cervarix is likely to attain blockbuster status in 2011, having received approval in the US market. The latter part of the forecast period will witness the launch of Novartis’ MenB, for the prevention of Neisseria meningitidis serogroup B infection.